CORE is a Clinical Operations Retreat for Executives - an event intended for senior decision-makers organized by Halloran Consulting Group. Our focus is on the pressing issues that keep you and your peers up at night.
We are thrilled to announce that Halloran has been recognized on the Inc. 5000 list for the fourth year running. Each year, Inc. magazine names the fastest growing private companies on a prestigious list that exemplifies a high level of success and transformation.
The Food and Drug Administration (FDA) granted orphan drug designation to CT-179, Curtana Pharmaceuticals’ lead Olig2 inhibitor for the treatment of gliomas, including glioblastoma (GBM) in adults and pediatric high-grade glioma in children.
While the healthcare industry’s tenet--to provide quality patient care and improve outcomes--has remained steadfast, there are some well-documented challenges increasingly impacting today’s medical device industry.